Tests zavegepant for migraine attacks in people using CGRP preventive medicines
Tests zavegepant to treat migraine attacks in adults already using CGRP preventive medicines.
Plain-language title generated from the registry record
Registry title: Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
Key facts
- Where
- Phoenix, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Mayo Clinic in ArizonaPhoenix, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06401642
- Record updated
- 17 September 2026
- Original description
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.Read full original descriptionShow less
A Study to Assess Effectiveness and Tolerability of Zavegepant as an Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Inclusion: Meets International Classification of Headache Disorders 3 (ICHD-3) diagnostic criteria for migraine with or without aura; At least 18 years of age; 2- 8 migraine attacks per month; Participants should be on a calcitonin gene-related peptide (CGRP)-targeting preventive migraine medication on a stable dose for a) ≥2 months prior to zavegepant treatment if an oral gepant or a monoclonal antibody (mAb) injected monthly, or b) at least two treatments if a mAb injected each 3 months; Atogepant; Eptinezumab; Erenumab; Fremanezumab; Galcanezumab; Rimegepant; Must have 4 or more migraine days per month, on average, during the 2 months prior to the Screening Visit, according to participant self-report.
Exclusion: Prior use of zavegepant and other gepants is permitted; Participants can be using migraine preventive medications/treatments in addition to the CGRP-targeting preventive treatment, as long as those treatments have been stable for at least two months at the time of enrollment; Additional Eligibility Criteria for Participants to Start on Rimegepant for Migraine Prevention; Primary headache disorders other than migraine (tension-type headache days are allowed); History of hypersensitivity reaction to zavegepant or to any of the components of zavegepant; Eligibility Notes; History of hypersensitivity reaction to rimegepant or to any of the components of rimegepant; Participants may have either episodic or chronic migraine.